Key result
Personalized pharmacotherapy remains essential for managing chronic and refractory angina as new treatments emerge.
A personalized approach to pharmacotherapy is essential for managing chronic and refractory angina.
Answers are grounded in this paper and cite their sources.
May support personalized regimens in refractory angina; leaves open validation of novel agents in prospective trials.
INTRODUCTION: century, there has been considerable advancement in the pharmacologic management of angina. Areas covered: Management of chronic angina is often challenging for clinicians. Despite introduction of several pharmacological agents in last few decades, a significant proportion of patients continue to experience symptoms (i.e., refractory angina) with subsequent disability. For the purpose of this review, we searched PubMed and Cochrane databases from inception to August 2016 for the most clinically relevant publications that guide current practice in angina therapy and its development. In this article, we briefly review the pathophysiology of angina and mechanism-based classification of current therapy. This is followed by evidence-based insight into the traditional and novel pharmacotherapeutic agents, highlighting their clinical usefulness. Expert opinion: Considering the wide array of available therapies with different mechanism efficacy and limiting factors, a personalized approach is essential, particularly for patients with refractory angina. Ongoing research with novel pharmacologic modalities is likely to provide new options for management of angina.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2017) conducted a review in Angina. Pharmacotherapy was evaluated. A personalized approach to pharmacotherapy is essential for managing chronic and refractory angina, with ongoing research likely to provide new treatment options.
Synapse has enriched 10 related papers. Consider them for comparative context: